Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company (BMS) reports a significant capital market event. The report date is November 10, 2025, covering an event that occurred on October 31, 2025. The filing details the completion of a public offering of senior unsecured notes by BMS Ireland Capital Funding Designated Activity Company, a wholly-owned subsidiary of BMS.
Key Financial Metrics and Capital Structure
The company completed a multi-tranche bond offering totaling €5.0 billion in aggregate principal amount. The notes are fully and unconditionally guaranteed on a senior unsecured basis by BMS. The specific tranches issued are as follows:
- 2030 Notes: €750 million at 2.973% interest.
- 2033 Notes: €1.15 billion at 3.363% interest.
- 2038 Notes: €1.15 billion at 3.857% interest.
- 2045 Notes: €750 million at 4.289% interest.
- 2055 Notes: €1.2 billion at 4.581% interest.
Interest payments for all series will commence on November 10, 2026. The filing does not provide specific revenue, profit, cash flow, or margin figures for the period, as this is a transactional filing rather than a periodic financial report.
Material Changes and Use of Proceeds
The primary material change is the increase in long-term debt obligations through the issuance of the new notes. The company intends to use the net proceeds from this offering, combined with approximately $3.0 billion of cash on hand, for the following purposes:
- To fund a tender offer to purchase various series of the company's outstanding notes.
- To pay fees and expenses associated with the tender offer and the new offering.
- To apply any remaining proceeds to general corporate purposes.
Outlook, Risks, and Covenants
The Indenture governing the notes includes customary covenants and restrictions. These include requirements for the Issuer to satisfy certain conditions before incurring debt secured by liens, engaging in sale/leaseback transactions, or merging with another entity. The notes are subject to customary events of default. The Issuer retains the option to redeem any series of notes in whole or in part at redemption prices set forth in the Indenture. The filing notes that information regarding representations and warranties in the Underwriting Agreement may change and should not be relied upon as characterizations of the actual state of facts.
Investor Verification Checklist
- Verify the exact amount of the tender offer for existing notes and the specific series targeted for repurchase.
- Confirm the total cash on hand available to supplement the net proceeds of the offering.
- Review the full text of the Base Indenture and First Supplemental Indenture (Exhibits 4.1 and 4.2) for specific redemption schedules and make-whole provisions.
- Monitor the impact of the new debt issuance on the company's overall leverage ratios and credit ratings.